Trials / Enrolling By Invitation
Enrolling By InvitationNCT04145375
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
- Status
- Enrolling By Invitation
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Zenith Epigenetics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Detailed description
This is an open label, non-randomized, single-arm continuation protocol study using ZEN003694. Patients who have completed participation in their original ("parent") ZEN003694 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in the continuation protocol. The patient must have been enrolled in a Zenith Epigenetics sponsored ZEN003694 therapeutic study to be eligible for participation in this continuation protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZEN003694 | Up to 120mg |
| DRUG | Enzalutamide | 160mg |
Timeline
- Start date
- 2019-11-12
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2019-10-30
- Last updated
- 2025-03-19
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04145375. Inclusion in this directory is not an endorsement.